Teligent, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. The company sells generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms. It also develops, manufactures, fills, and packages topical semi-solid and liquid products for branded and generic pharmaceutical customers, as well as for over-the-counter and cosmetic markets. The company's products are used in various applications that range from cosmetics and cosmeceuticals to the prescription treatment of conditions, such as dermatitis, psoriasis, and eczema. In addition, it offers contract manufacturing and formulation services. Teligent, Inc. sells its products through national chain drug stores, drug wholesalers, distributors, and group purchasing organizations. The company was formerly known as IGI Laboratories, Inc. and changed its name to Teligent, Inc. in October 2015. Teligent, Inc. was founded in 1977 and is based in Buena, New Jersey.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TLGT
CUSIPN/A
Phone856-697-1441
Debt
Debt-to-Equity Ratio3.07
Current Ratio2.73
Quick Ratio1.69
Price-To-Earnings
Trailing P/E Ratio-21.42
Forward P/E Ratio-68.00
P/E GrowthN/A
Sales & Book Value
Annual Sales$67.25 million
Price / Sales3.25
Cash Flow$0.0749 per share
Price / Cash54.45
Book Value$0.84 per share
Price / Book4.86
Profitability
EPS (Most Recent Fiscal Year)($0.19)
Net Income$-15,190,000.00
Net Margins-28.98%
Return on Equity-27.25%
Return on Assets-6.94%
Miscellaneous
Employees183
Outstanding Shares53,510,000
Market Cap$210.31
Teligent (NASDAQ:TLGT) Frequently Asked Questions
What is Teligent's stock symbol?
Teligent trades on the NASDAQ under the ticker symbol "TLGT."
How were Teligent's earnings last quarter?
Teligent Inc (NASDAQ:TLGT) announced its earnings results on Tuesday, May, 8th. The company reported ($0.04) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.03) by $0.01. The company had revenue of $14.55 million for the quarter, compared to analyst estimates of $15.62 million. Teligent had a negative return on equity of 27.25% and a negative net margin of 28.98%. View Teligent's Earnings History.
What price target have analysts set for TLGT?
3 Wall Street analysts have issued 1 year price targets for Teligent's stock. Their predictions range from $4.00 to $9.00. On average, they expect Teligent's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 71.6% from the stock's current price. View Analyst Ratings for Teligent.
What is the consensus analysts' recommendation for Teligent?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teligent in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
What are Wall Street analysts saying about Teligent stock?
Here are some recent quotes from research analysts about Teligent stock:
- 1. According to Zacks Investment Research, "Teligent, Inc. is a specialty generic pharmaceutical company, develops, manufactures and markets topical formulations primarily in the United States. It sells generic pharmaceutical products in topical, injectable, complex and ophthalmic dosage forms. Teligent Inc., formerly known as IGI Laboratories, Inc., is based in Buena, New Jersey. " (6/22/2018)
- 2. Canaccord Genuity analysts commented, "We’re confident that the company’s revised expectations are achievable and delays at the agency will resolve in short order. We continue to view Teligent as a uniquely positioned generic company poised for meaningful growth over the next several years. We maintain our BUY rating and $11 price target on TLGT shares. Light revenue due to lidocaine ointment and Zantac; lidocaine solution a surprising star in the report. Teligent’s 2Q/17 revenue was $18.4 mm compared to our $19mm estimate and $20.3 mm consensus. In our post-launch thoughts, we believed investors were expecting a light quarter and potential downward revision to 2H/17 expectations. Adjusted loss per share was ($0.01) compared to our EPS estimate of +$0.01 and consensus of +$0.02. Teligent saw incremental competition and double-digit price erosion on lidocaine ointment and a return of a competitor on Zantac injection coupled with lower-than-expected Zantac utilization rates due to recent inventory shortages that changed physician use patterns." (8/8/2017)
Who are some of Teligent's key competitors?
Some companies that are related to Teligent include ANI Pharmaceuticals Inc Common Stock (ANIP), Amarin (AMRN), Homology Medicines (FIXX), NuCana (NCNA), Eidos Therapeutics (EIDX), Inflarx (IFRX), Rocket Pharmaceuticals (RCKT), Kiniksa Pharmaceuticals (KNSA), CymaBay Therapeutics (CBAY), Amphastar Pharmaceuticals (AMPH), AMAG Pharmaceuticals (AMAG), Adamas Pharmaceuticals (ADMS), AC Immune (ACIU), Cara Therapeutics (CARA) and Aptinyx (APTX).
Who are Teligent's key executives?
Teligent's management team includes the folowing people:
- Mr. Jason Grenfell-Gardner M.B.A., M.B.A, Pres, CEO & Director (Age 43)
- Mr. Stephen Richardson, Chief Scientific Officer (Age 52)
- Mr. Martin Wilson, Gen. Counsel (Age 41)
- Mr. Damian Finio, Corp. Sec. & CFO (Age 48)
- Ms. Nadya Lawrence, Sr. VP of Technical Services (Age 49)
Has Teligent been receiving favorable news coverage?
Media coverage about TLGT stock has been trending somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Teligent earned a news impact score of 0.16 on Accern's scale. They also gave headlines about the company an impact score of 46.60 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Who are Teligent's major shareholders?
Teligent's stock is owned by many different of retail and institutional investors. Top institutional investors include Sanders Morris Harris LLC (2.78%). Company insiders that own Teligent stock include Carole Ben-Maimon, Jenniffer Collins, Stephen Richardson and Steven H Koehler. View Institutional Ownership Trends for Teligent.
Which institutional investors are buying Teligent stock?
TLGT stock was acquired by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC. Company insiders that have bought Teligent stock in the last two years include Carole Ben-Maimon, Jenniffer Collins, Stephen Richardson and Steven H Koehler. View Insider Buying and Selling for Teligent.
How do I buy shares of Teligent?
Shares of TLGT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Teligent's stock price today?
One share of TLGT stock can currently be purchased for approximately $4.08.
How big of a company is Teligent?
Teligent has a market capitalization of $210.31 million and generates $67.25 million in revenue each year. The company earns $-15,190,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. Teligent employs 183 workers across the globe.
How can I contact Teligent?
Teligent's mailing address is 105 LINCOLN AVENUE, BUENA NJ, 08310. The company can be reached via phone at 856-697-1441 or via email at [email protected]
MarketBeat Community Rating for Teligent (NASDAQ TLGT)
MarketBeat's community ratings are surveys of what our community members think about Teligent and other stocks. Vote "Outperform" if you believe TLGT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TLGT will underperform the S&P 500 over the long term. You may vote once every thirty days.
